Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmuCellICCC +4.00%54 Net Current Asset Value is $0.64 as of Jun. 2026, which is 96% below its 10-year median of 15.70. GuruFocus rates ICCC with a GF Score™ of 54/100 and a GF Value™ of $6.91 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 928 Biotechnology companies, ImmuCell ranks worse than 82% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
ImmuCell's net current asset value per share for the quarter that ended in Jun. 2026 was $0.64.
The historical rank and industry rank for ImmuCell's Net Current Asset Value or its related term are showing as below:
ICCC'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.08 Med: 15.7 Max: 964
Current: 15.83
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of ImmuCell was 964.00. The lowest was 3.08. And the median was 15.70.
ICCC's Price-to-Net-Current-Asset-Value is ranked worse than 82% of 928
companies
in the Biotechnology industry
Industry Median: 4.975
vs ICCC: 15.83
ImmuCell (NAS:ICCC) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
ImmuCell Net Current Asset Value Related Terms
ImmuCell Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for ImmuCell's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICCC vs COYA, ENTX, BDTX: Net Current Asset Value Comparison
For the Biotechnology subindustry, ImmuCell's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuCell Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ImmuCell's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where ImmuCell's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.64 mean?
ImmuCell (ICCC) has a Net Current Asset Value of $0.64 as of Jun. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on ImmuCell and its competitors. This is 96% below median its historical median of 15.70. Over the past decade, ImmuCell's Net Current Asset Value has ranged from 3.08 to 964.00. According to the industry distribution chart, ImmuCell ranks #761 out of 928 companies in the Biotechnology industry, placing it in the top 82%.
Is ImmuCell's Net Current Asset Value too high?
ImmuCell's current Net Current Asset Value of $0.64 is 96% below median its 10-year median of 15.70. Over the past 10 years, this metric has ranged from a low of 3.08 to a high of 964.00. The Biotechnology industry median Net Current Asset Value is 4.98. ImmuCell's value of $0.64 is 87.1% below this industry median. Based on the distribution chart, ImmuCell ranks #761 out of 928 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ImmuCell has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's Net Current Asset Value compare to COYA and ENTX?
According to the Biotechnology industry distribution chart, ImmuCell ranks #761 out of 928 companies for Net Current Asset Value. This places ImmuCell in the lower half of its industry. The industry median Net Current Asset Value is 4.98. ImmuCell's value of $0.64 is 87.1% below this benchmark. Historically, ImmuCell's own Net Current Asset Value has ranged from 3.08 to 964.00 over the past decade. While the company's 10-year median is 15.70 vs. the industry median of 4.98, ImmuCell has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.98, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ImmuCell's current Net Current Asset Value of $0.64 is 87.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on ImmuCell and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImmuCell's current Net Current Asset Value is $0.64, which is 96% below median its own 10-year median of 15.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (ICCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.91, compared to a current price of $10.13 — trading 46.6% above its estimated fair value. The current Net Current Asset Value is $0.64, which is 96% below median its 10-year median of 15.70 and 87.1% below the Biotechnology industry median of 4.98. ImmuCell's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For ImmuCell (ICCC), the current Net Current Asset Value is $0.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImmuCell (ICCC) Overvalued in 2026?
Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued.
The current stock price of $10.13 is trading 46.6% above its estimated GF Value™ of $6.91.
GuruFocus considers ImmuCell to be Significantly Overvalued.
Key valuation signals for ICCC:
Net Current Asset Value: $0.64 (96% below median its 10-year median of 15.70)
GF Value™: $6.91 vs. price of $10.13 (46.6% above fair value)
Industry Position: 87.1% below the Biotechnology median (#761 of 928)
No single metric tells the full story. See the ICCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
54GF Score
Get the complete analysis for ICCC
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICCC has been successfully added to your 
